MISSISSAUGA, ONTARIO,--(Marketwire - November 28, 2008) - BioSyent Inc. (“BioSyent”)(TSX VENTURE: RX) today released a summary of its financial results for the third quarter 2008. Sales decreased by 8.9% from $1,050,013 in first nine months of 2007 to $956,414 in first nine months of 2008. The company incurred a loss of ($118,363) in the first nine months of 2008 compared to a gain of $31,410 in first nine months of 2007. This loss is predominantly due to the higher pharmaceutical operating expenses for the establishment of the hospital division and the launch of Ciprofloxacin Injection, which was first shipped in May 2008.
